Molecular mechanisms underlying the development of familial breast and ovarian cancer have become the focuses of many laboratories following the cloning of breast cancer susceptibility gene BRCA1. In the last four years since this grant was first funded, our understanding of BRCA1 has expanded at a rapid pace. BRCA1 contains two functional motifs: the N-terminal RING domain and the C-terminal BRCA1 C-terminus (BRCT) domain. We now know that the functional significance of two recognizable motifs within BRCA1. Studies from us have revealed that BRCA1 BRCT domain is a phospho-protein binding domain. Through this reversible interaction domain, BRCA1 associates with many binding-partners and participates in multiple cellular functions. We also know that the N-terminal Ring domain of BRCA1 has intrinsic E3 ubiquitin ligase activity. However, it is not clear how these two domains function together in ensuring genomic stability. Base on our preliminary studies, we propose that BRCA1 recruits its substrates through the BRCT domain, modifies these substrates via the N-terminal Ring domain-dependent ubiquitination reactions, and thus regulates diverse cellular processes. Here, we will test this hypothesis.
In Specific Aim 1, we will examine whether a known BRCA1 BRCT domain-associated protein is a direct substrate of BRCA1. In preliminary studies, we have shown that topoisomerase II alpha is ubiquitinated and regulated by BRCA1.
In Specific Aim 2, we will determine whether the interaction between topoisomerase II and BRCA1 depends on the intact BRCA1 BRCT domains and explore how this interaction is regulated in cells. We have identified one new BRCA1 BRCT domain-associated protein.
In Specific Aim 3, we will further study its interaction with BRCA1 and how this BRCA1-associated protein contributes to BRCA1 functions. Collectively, these studies will provide novel insights into the regulation and tumor suppression function of BRCA1.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA089239-12
Application #
7797666
Study Section
Special Emphasis Panel (ZRG1-ONC-U (90))
Program Officer
Pelroy, Richard
Project Start
2000-12-01
Project End
2011-06-30
Budget Start
2010-05-01
Budget End
2011-06-30
Support Year
12
Fiscal Year
2010
Total Cost
$245,461
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Radiation-Diagnostic/Oncology
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Zhang, Aili; Peng, Bo; Huang, Ping et al. (2017) The p53-binding protein 1-Tudor-interacting repair regulator complex participates in the DNA damage response. J Biol Chem 292:6461-6467
Li, Xu; Wang, Wenqi; Xi, Yuanxin et al. (2016) FOXR2 Interacts with MYC to Promote Its Transcriptional Activities and Tumorigenesis. Cell Rep 16:487-497
Lee, Yuan-Cho; Zhou, Qing; Chen, Junjie et al. (2016) RPA-Binding Protein ETAA1 Is an ATR Activator Involved in DNA Replication Stress Response. Curr Biol 26:3257-3268
Li, Nan; Feng, Lin; Liu, Hui et al. (2016) PARP Inhibition Suppresses Growth of EGFR-Mutant Cancers by Targeting Nuclear PKM2. Cell Rep :
Wang, Wenqi; Xiao, Zhen-Dong; Li, Xu et al. (2015) AMPK modulates Hippo pathway activity to regulate energy homeostasis. Nat Cell Biol 17:490-9
Li, Xu; Wang, Wenqi; Chen, Junjie (2015) From pathways to networks: connecting dots by establishing protein-protein interaction networks in signaling pathways using affinity purification and mass spectrometry. Proteomics 15:188-202
Wang, Wenqi; Li, Nan; Li, Xu et al. (2015) Tankyrase Inhibitors Target YAP by Stabilizing Angiomotin Family Proteins. Cell Rep 13:524-532
Wang, Wenqi; Li, Xu; Lee, Moonsup et al. (2015) FOXKs promote Wnt/?-catenin signaling by translocating DVL into the nucleus. Dev Cell 32:707-18
Wang, Wenqi; Li, Xu; Huang, Jun et al. (2014) Defining the protein-protein interaction network of the human hippo pathway. Mol Cell Proteomics 13:119-31
Wang, Jiadong; Aroumougame, Asaithamby; Lobrich, Markus et al. (2014) PTIP associates with Artemis to dictate DNA repair pathway choice. Genes Dev 28:2693-8

Showing the most recent 10 out of 71 publications